新美星 reported revenue of ¥0.71B for the period ended 2026-06-30, +22.1% year on year. Net income was ¥0.06B, a 7.9% net margin on a 29.2% gross margin. The largest revenue line is 液态食品包装机械制造业务 at 98% of the total. Free cash flow for the period was ¥-0.01B.
| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥0.71B | +22.1% |
| Gross profit | ¥0.21B | — |
| Operating income | ¥0.06B | — |
| Net income | ¥0.06B | +34.4% |
| Gross margin | 29.2% | Net margin 7.9% |
| Revenue Q/Q | +17.4% | — |
| Segment | Revenue | Share |
|---|---|---|
| 液态食品包装机械制造业务 | ¥0.69B | 97.6% |
| 埃塞瓶坯制造业务组 | ¥0.02B | 2.4% |
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥0.50B | 70.8% |
| R&D | ¥0.03B | 4.6% |
| SG&A | ¥0.06B | 9.1% |
| Tax & other | ¥0.01B | 0.8% |
| Item | Amount |
|---|---|
| Total assets | ¥2.73B |
| Total liabilities | ¥1.98B |
| Shareholders' equity | ¥0.74B |
| Equity / assets | 27.3% |
| Operating cash flow | ¥-0.01B |
| Capital expenditure | ¥0.00B |
| Free cash flow | ¥-0.01B |
| Cash conversion (OCF / net income) | 127% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
金冠股份 ・ 雪榕生物 ・ 中亚股份 ・ 恒实科技 ・ 友讯达 ・ 三德科技 ・ 久之洋 ・ 海波重科 ・ 新迅达 ・ 新光药业 ・ 科大国创 ・ 爱司凯
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies